W Brinjikji1, D F Kallmes2, H J Cloft2, G Lanzino2. 1. From the Departments of Radiology (W.B., D.F.K., H.J.C., G.L.) Brinjikji.waleed@mayo.edu. 2. From the Departments of Radiology (W.B., D.F.K., H.J.C., G.L.) Neurosurgery (D.F.K., H.J.C., G.L.), Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND AND PURPOSE: Treatment of cerebral aneurysms with flow diverters often mandates placement of the device across the ostia of major branches of the internal carotid artery. We determined the patency rates of the anterior choroidal artery after placement of flow-diversion devices across its ostium. MATERIALS AND METHODS: We analyzed a consecutive series of patients in whom a Pipeline Embolization Device was placed across the ostium of an angiographically visible anterior choroidal artery while treating the target aneurysm. Patency of the anterior choroidal artery after Pipeline Embolization Device placement was determined at immediate postoperative and follow-up angiography. Data on pretreatment aneurysm rupture status, concomitant coiling, number of Pipeline Embolization Devices used, neurologic status at follow-up, and follow-up MR imaging/CT findings were collected. RESULTS: Fifteen patients with 15 treated aneurysms were included in this study. In the immediate postprocedural setting, the anterior choroidal artery was patent on posttreatment angiography for all 15 patients. Of the 14 patients with follow-up angiography at least 6 months after Pipeline Embolization Device placement, 1 (7%) had occlusion of the anterior choroidal artery and 14 had a patent anterior choroidal artery (93%). No patients had new neurologic symptoms or stroke related to anterior choroidal artery occlusion at follow-up. Of the 9 patients with follow-up CT or MR imaging, none had infarction in the vascular territory of the anterior choroidal artery. CONCLUSIONS: In this small study, placement of a Pipeline Embolization Device across the anterior choroidal artery ostium resulted in occlusion of the artery in only 1 patient. It was not associated with ischemic changes in the distribution of the anterior choroidal artery in any patient.
BACKGROUND AND PURPOSE: Treatment of cerebral aneurysms with flow diverters often mandates placement of the device across the ostia of major branches of the internal carotid artery. We determined the patency rates of the anterior choroidal artery after placement of flow-diversion devices across its ostium. MATERIALS AND METHODS: We analyzed a consecutive series of patients in whom a Pipeline Embolization Device was placed across the ostium of an angiographically visible anterior choroidal artery while treating the target aneurysm. Patency of the anterior choroidal artery after Pipeline Embolization Device placement was determined at immediate postoperative and follow-up angiography. Data on pretreatment aneurysm rupture status, concomitant coiling, number of Pipeline Embolization Devices used, neurologic status at follow-up, and follow-up MR imaging/CT findings were collected. RESULTS: Fifteen patients with 15 treated aneurysms were included in this study. In the immediate postprocedural setting, the anterior choroidal artery was patent on posttreatment angiography for all 15 patients. Of the 14 patients with follow-up angiography at least 6 months after Pipeline Embolization Device placement, 1 (7%) had occlusion of the anterior choroidal artery and 14 had a patent anterior choroidal artery (93%). No patients had new neurologic symptoms or stroke related to anterior choroidal artery occlusion at follow-up. Of the 9 patients with follow-up CT or MR imaging, none had infarction in the vascular territory of the anterior choroidal artery. CONCLUSIONS: In this small study, placement of a Pipeline Embolization Device across the anterior choroidal artery ostium resulted in occlusion of the artery in only 1 patient. It was not associated with ischemic changes in the distribution of the anterior choroidal artery in any patient.
Authors: Waleed Brinjikji; Harry J Cloft; David Fiorella; Giuseppe Lanzino; David F Kallmes Journal: J Neurointerv Surg Date: 2011-12-02 Impact factor: 5.836
Authors: N Adeeb; C J Griessenauer; A A Dmytriw; H Shallwani; R Gupta; P M Foreman; H Shakir; J Moore; N Limbucci; S Mangiafico; A Kumar; C Michelozzi; Y Zhang; V M Pereira; C C Matouk; M R Harrigan; A H Siddiqui; E I Levy; L Renieri; T R Marotta; C Cognard; C S Ogilvy; A J Thomas Journal: AJNR Am J Neuroradiol Date: 2018-06-07 Impact factor: 3.825
Authors: M R Levitt; M S Park; F C Albuquerque; K Moon; M Y S Kalani; C G McDougall Journal: AJNR Am J Neuroradiol Date: 2015-10-01 Impact factor: 3.825
Authors: G Foa Torres; F Roca; A Noguera; J Godes; S Petrocelli; I Aznar; S Ales; P Muszynski; R Maehara; M Vicente; J M Pumar Journal: Interv Neuroradiol Date: 2018-05-02 Impact factor: 1.610
Authors: Brian P Walcott; Clemens Reinshagen; Christopher J Stapleton; Omar Choudhri; Vitaliy Rayz; David Saloner; Michael T Lawton Journal: J Cereb Blood Flow Metab Date: 2016-03-23 Impact factor: 6.200
Authors: Mehdi Abbasi; Luis E Savasatano; Waleed Brinjikji; Kevin M Kallmes; Nick Mikoff; Natalie Reierson; Mohamed Abdelmegeed; John Pederson; Beth Warren; Jillienne C Touchette; Sarah Khan; Shelby Kamrowski; Averi Barrett; David F Kallmes; Ramanathan Kadirvel Journal: Interv Neuroradiol Date: 2021-06-22 Impact factor: 1.764